Company information
- Ticker
- KBLB
- Country
- United States
- Sector
- Materials
- Industry
- Chemicals
Kraig Biocraft Laboratories Business Summary
Kraig Biocraft Laboratories, Inc. (KBLB) is a biotechnology firm specializing in the development and commercialization of recombinant spider silk through a proprietary transgenic silkworm platform. The company generates revenue primarily through the commercial sale of high-performance fibers, technology licensing, and government contracts, operating within the technical textiles and specialty materials segments. As of early 2026, KBLB is executing a massive production scale-up in Southeast Asia, targeting a monthly output of 10 metric tons of recombinant cocoons by May 2026. This vertically integrated model leverages three operational rearing centers and dedicated mulberry feedstock to produce trademarked fibers such as Dragon Silk, Monster Silk, and Spydasilk. KBLB competes directly with synthetic biology firms like Spiber, AMSilk, and Bolt Threads, distinguishing itself by utilizing existing global silk infrastructure to achieve industrial-scale production at a lower cost-per-kilogram than fermentation-based alternatives. Leadership is spearheaded by Founder and CEO Kim K. Thompson, a University of Michigan Law graduate whose background in economics and small-cap research drove the company’s initial intellectual property strategy. The executive team includes COO Jonathan Rice, a chemical engineer with extensive experience in technology commercialization, and Chief Scientist Xiaoli Zhang, who oversees the firm’s advanced genetic engineering initiatives. The company’s operational footprint in Vietnam is managed by Kenneth Le, President of Prodigy Textiles and Director of Government Relations. KBLB’s Board of Directors features high-pedigree members such as Anurag Gupta, a former executive at IHS Markit and BrightPoint, and Gregory Scheessele, a manufacturing veteran with 40 years of leadership at General Motors and Pall Corporation. Notable institutional interest has historically included Hurley Capital, LLC, alongside significant research funding and development contracts from the U.S. Army for ballistic-grade protective textiles.